2019-004132-37: A clinical study to determine if a potential new drug (SCD411) is similar to the marketed product Eylea® in the efficacy, is safe and similar tolerable and distributed, by testing its effect on the body in patients with Neovascular Age-related Macular Degeneration |
|
|
| Not yet recruiting | 3 | 576 | Europe, RoW | SCD411, Eylea, SCD411, Solution for injection, Eylea | SamChunDang Pharm. Co. Ltd., Sam Chun Dang Pharm. Co. Ltd, SamChunDang Pharm. Co. Ltd. | Neovascular Age-related Macular Degeneration, Age-related macular degeneration (AMD) is a disease that impacts the central area of the retina in the eye, called the macula. AMD is a leading cause of blindness, Diseases [C] - Eye Diseases [C11] | | | | |
| Completed | 3 | 576 | Europe, Japan, US, RoW | SCD411, Aflibercept, Eylea® | Sam Chun Dang Pharm. Co. Ltd., SamChunDang Pharm. Co. Ltd. | Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration | 09/22 | 09/22 | | |
